Entrada Therapeutics Inc
TRDA
Get informed when a big investor buys or sells
+ FollowMarket Cap$271.74M
Close$
$5.55
22.5% downside
Current Fair Value
22.5% downsideOvervalued by 22.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $271.74 Million |
|---|---|
| Enterprise Value | $221.18 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.47 |
| Beta | -0.26 |
| Outstanding Shares | 42,221,665 |
Return
| Return on Equity | -71.02% |
|---|---|
| Return on Assets | -55.47% |
| Return on Invested Capital | -61.68% |
Valuation & Multiples
| P/E Ratio | -1.76 |
|---|---|
| PEG | 223.53 |
| Price to Sales | - |
| Price to Book Ratio | 1.43 |
| Enterprise Value to Revenue | 47.2 |
| Enterprise Value to EBIT | -1.29 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.22 |
| Debt to Equity | 0.21 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-1.07
Average shareholder expectationRevenue Estimate
$2.23 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.98
Average shareholder expectationRevenue Estimate
$2.13 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 70.00%▲ 8.42% |
|---|---|
| Total Invested | $216.25M▼ 32.72% |
| Investors Holding | 130▲ 11.00% |
ESG Score
No data